Campaign imagery

Vivotif® (Typhoid Vaccine Live Oral Ty21a) Capsules

Vivotif® is indicated for active oral immunisation against typhoid fever, caused by Salmonella enterica serovar Typhi, (S. Typhi), in adults and children aged five years and older. This vaccine should be used in accordance with official recommendations.1

Click for Vivotif® prescribing information (External Link)

Indication:

Vivotif® is indicated for active oral immunisation against typhoid fever, caused by Salmonella enterica serovar Typhi, (S. Typhi), in adults and children aged five years and older. This vaccine should be used in accordance with official recommendations.1
 

 

Vaccination with Vivotif®*

  • Oral vaccine with three doses taken over five days1
  • Protection commences approximately seven to ten days after ingesting the third dose of vaccine1
  • Ty21a has been shown to trigger humoral and cellular immunity both locally and systemically1
  • The three-dose regimen of enteric-coated capsules in an every other day schedule has been shown in a field trial to have a protective efficacy of 71% (95% CI 35%–87%) during the first year (n=22170)1,2,†
Vivotif® (Typhoid Vaccine Live Oral Ty21a) Capsules pack shot and blister pack

Help prevent typhoid fever with 3 capsules of Vivotif®

Vivotif® is an oral vaccine consisting of 3 capsules taken on alternating days for a period of 5 days (Days 1, 3 and 5). The capsule should be taken with cold or lukewarm water (temperature not more than 37°C) on an empty stomach and at least one hour before the next meal.1

The entire vaccination schedule should be completed at least one week prior to travel to an endemic area.1 See the Summary of Product Characteristics for Vivotif® for further information on administration of the medicinal product.

 

Vaccination schedule

 

This figure has been produced by Bavarian Nordic based on reference 1.

Vivotif® does not provide 100% protection against typhoid fever. Vaccinees should adhere to hygiene advice and exercise caution regarding food and water consumed in typhoid-affected areas.1

 

 

 

Vivotif® may provide both cellular and humoral protection

Vivotif® contains microorganisms of the attenuated S. Typhi strain Ty21a. Ty21a has been shown to trigger humoral and cellular immunity both locally and systemically.1 Vaccination with Vivotif® thus may provide two types of protection, similar to the natural immune response.1,3

 

 

 

Revaccination

Revaccination is recommended at three years following the most recent vaccination for all individuals. Revaccination comprises the ingestion of three capsules on Days 1, 3, and 5, as for the original vaccination schedule.1

 

 

 

Vivotif® mechanism of action video

71% protective efficacy was shown during the first year after vaccination1†

In a randomised, placebo-controlled, double-blind field trial, the three-dose regimen of enteric-coated capsules (n=22170) in an every other day schedule has been shown to have a protective efficacy over one, three and seven years of 71%, 67% and 62%, respectively.1,2,4,†,‡,§

 

 

Protective efficacy of Vivotif®1

Protective efficacy of Vivotif® (Typhoid Vaccine Live Oral Ty21a) Capsules graph

This figure has been produced by Bavarian Nordic based on references 1, 2 and 4.

 

Adverse reactions and contraindications

The table below shows adverse reactions of Vivotif® reported in clinical trials.

Adverse reactions reported in clinical trials1,a,b

Adverse Reactions Frequency
Nervous system disorders
Headache Common
Gastrointestinal disorders
Abdominal pain, nausea, vomiting, diarrhoea Common
Skin and subcutaneous tissue disorders
Rash Common
General disorders and administration site conditions
Pyrexia Common

This table has been adapted by Bavarian Nordic from reference 1.

Please refer to the Vivotif® Summary of Product Characteristics for full information on adverse reactions.

aMost adverse reactions have been mild. One isolated, non-fatal anaphylactic shock considered to be an allergic reaction to the vaccine was reported.

bThe adverse reaction frequency classification used is as follows: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).

Contraindications1

  • Hypersensitivity to any component of the vaccine described in the Vivotif® Summary of Product Characteristics
  • Allergic reaction to previous ingestion of the product
  • Congenital or acquired immune deficiency (including patients receiving immunosuppressive or antimitotic drugs)
  • Acute febrile illness or acute gastrointestinal illness. Vaccination should be postponed until after recovery

Vivotif® (Typhoid Vaccine, Live, Oral)

PIP CODE 0834994

Please note: Prices shown do not include any additional discounts and delivery charges you may be eligible for.

Find out more

Published Date: 7 October 2026

Vivotif® and its respective logo are registered trademarks of Bavarian Nordic A/S.

  1. Vivotif® Summary of Product Characteristics.
  2. Levine MM, et al. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine. 1999;17(Suppl 2):S22–S27.
  3. Kantele A, et al. Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines - a randomized trial. PLoS One. 2013;8(4):e60583.
  4. Levine MM, et al. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet. 1987;329:1049–1052.

Vivotif® is indicated for active oral immunisation against typhoid fever, caused by Salmonella enterica serovar Typhi, (S. Typhi), in adults and children aged five years and older. This vaccine should be used in accordance with official recommendations.1

Vivotif® does not provide 100% protection against typhoid fever. Vaccinees should adhere to hygiene advice and exercise caution regarding food and water consumed in typhoid-affected areas.1

The most frequent adverse reactions have been abdominal pain, nausea, headache, fever, diarrhoea, vomiting, and skin rash. Most adverse reactions have been mild. One isolated, non-fatal anaphylactic shock considered to be an allergic reaction to the vaccine was reported.1

*Vivotif® is contraindicated in individuals with hypersensitivity to any component of the vaccine described in the Summary of Product Characteristics, or in individuals who have had an allergic reaction to previous ingestion of the product. Contraindications also include individuals with congenital or acquired immune deficiency (including patients receiving immunosuppressive or antimitotic drugs). For individuals with acute febrile or acute gastrointestinal illness, vaccination should be postponed until after recovery.1

Please refer to the Vivotif® Summary of Product Characteristics for full information.

†Protective efficacy (1 year) of 71% was shown in a clinical field trial (n=22170, 99% aged 6–19 years, 1% aged 19–21, 95% CI: 35%–87%).1,2,4

‡Protective efficacy (over 3 years) of 67% was shown in a clinical field trial (n=22170, 99% aged 6–19 years, 1% aged 19–21, 95% CI: 47%–79% p<0.001).1,2,4

§Protective efficacy (over 7 years) of 62% was shown in a clinical field trial (n=22170, 99% aged 6–19 years, 1% aged 19–21, 95% CI: 48%–73% p<0.001).1,2,4

Abbreviations:
CI, confidence interval; n, number of participants per parameter.

 

Click for Vivotif® prescribing information (External Link)